Estimates of PFS and overall survival in the total cohort and PFS according to mutation status, B2M, and posttreatment MRD. (A) PFS and survival in the total cohort. (B) PFS according to mutation status. (C) PFS according to mutation status and baseline B2M. (D) Six-month landmark PFS according to mutation status and achievement of posttreatment MRD-negativity.